Cargando…

In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes

In this study, paclitaxel (PTX)-loaded pH-responsive niosomes modified with ergosterol were developed. This new formulation was characterized in terms of size, morphology, encapsulation efficiency (EE), and in vitro release at pH 5.2 and 7.4. The in vitro efficacy of free PTX and niosome/PTX was ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Barani, Mahmood, Hajinezhad, Mohammad Reza, Sargazi, Saman, Rahdar, Abbas, Shahraki, Sheida, Lohrasbi-Nejad, Azadeh, Baino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643297/
https://www.ncbi.nlm.nih.gov/pubmed/34862910
http://dx.doi.org/10.1007/s10856-021-06623-6
_version_ 1784609855114313728
author Barani, Mahmood
Hajinezhad, Mohammad Reza
Sargazi, Saman
Rahdar, Abbas
Shahraki, Sheida
Lohrasbi-Nejad, Azadeh
Baino, Francesco
author_facet Barani, Mahmood
Hajinezhad, Mohammad Reza
Sargazi, Saman
Rahdar, Abbas
Shahraki, Sheida
Lohrasbi-Nejad, Azadeh
Baino, Francesco
author_sort Barani, Mahmood
collection PubMed
description In this study, paclitaxel (PTX)-loaded pH-responsive niosomes modified with ergosterol were developed. This new formulation was characterized in terms of size, morphology, encapsulation efficiency (EE), and in vitro release at pH 5.2 and 7.4. The in vitro efficacy of free PTX and niosome/PTX was assessed using MCF7, Hela, and HUVEC cell lines. In order to evaluate the in vivo efficacy of niosomal PTX in rats as compared to free PTX, the animals were intraperitoneally administered with 2.5 mg/kg and 5 mg/kg niosomal PTX for two weeks. Results showed that the pH-responsive niosomes had a nanometric size, spherical morphology, 77% EE, and pH-responsive release in pH 5.2 and 7.4. Compared with free PTX, we found markedly lower IC50s when cancer cells were treated for 48 h with niosomal PTX, which also showed high efficacy against human cancers derived from cervix and breast tumors. Moreover, niosomal PTX induced evident morphological changes in these cell lines. In vivo administration of free PTX at the dose of 2.5 mg/kg significantly increased serum biochemical parameters and liver lipid peroxidation in rats compared to the control rats. The situation was different when niosomal PTX was administered to the rats: the 5 mg/kg dosage of niosomal PTX significantly increased serum biochemical parameters, but the group treated with the 2.5 mg/kg dose of niosomal PTX showed fewer toxic effects than the group treated with free PTX at the same dosage. Overall, our results provide proof of concept for encapsulating PTX in niosomal formulation to enhance its therapeutic efficacy. [Image: see text]
format Online
Article
Text
id pubmed-8643297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-86432972021-12-15 In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes Barani, Mahmood Hajinezhad, Mohammad Reza Sargazi, Saman Rahdar, Abbas Shahraki, Sheida Lohrasbi-Nejad, Azadeh Baino, Francesco J Mater Sci Mater Med Biocompatibility Studies In this study, paclitaxel (PTX)-loaded pH-responsive niosomes modified with ergosterol were developed. This new formulation was characterized in terms of size, morphology, encapsulation efficiency (EE), and in vitro release at pH 5.2 and 7.4. The in vitro efficacy of free PTX and niosome/PTX was assessed using MCF7, Hela, and HUVEC cell lines. In order to evaluate the in vivo efficacy of niosomal PTX in rats as compared to free PTX, the animals were intraperitoneally administered with 2.5 mg/kg and 5 mg/kg niosomal PTX for two weeks. Results showed that the pH-responsive niosomes had a nanometric size, spherical morphology, 77% EE, and pH-responsive release in pH 5.2 and 7.4. Compared with free PTX, we found markedly lower IC50s when cancer cells were treated for 48 h with niosomal PTX, which also showed high efficacy against human cancers derived from cervix and breast tumors. Moreover, niosomal PTX induced evident morphological changes in these cell lines. In vivo administration of free PTX at the dose of 2.5 mg/kg significantly increased serum biochemical parameters and liver lipid peroxidation in rats compared to the control rats. The situation was different when niosomal PTX was administered to the rats: the 5 mg/kg dosage of niosomal PTX significantly increased serum biochemical parameters, but the group treated with the 2.5 mg/kg dose of niosomal PTX showed fewer toxic effects than the group treated with free PTX at the same dosage. Overall, our results provide proof of concept for encapsulating PTX in niosomal formulation to enhance its therapeutic efficacy. [Image: see text] Springer US 2021-12-04 2021 /pmc/articles/PMC8643297/ /pubmed/34862910 http://dx.doi.org/10.1007/s10856-021-06623-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Biocompatibility Studies
Barani, Mahmood
Hajinezhad, Mohammad Reza
Sargazi, Saman
Rahdar, Abbas
Shahraki, Sheida
Lohrasbi-Nejad, Azadeh
Baino, Francesco
In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title_full In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title_fullStr In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title_full_unstemmed In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title_short In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes
title_sort in vitro and in vivo anticancer effect of ph-responsive paclitaxel-loaded niosomes
topic Biocompatibility Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643297/
https://www.ncbi.nlm.nih.gov/pubmed/34862910
http://dx.doi.org/10.1007/s10856-021-06623-6
work_keys_str_mv AT baranimahmood invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT hajinezhadmohammadreza invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT sargazisaman invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT rahdarabbas invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT shahrakisheida invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT lohrasbinejadazadeh invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes
AT bainofrancesco invitroandinvivoanticancereffectofphresponsivepaclitaxelloadedniosomes